Investors


 9 May 2017

Eyevensys Announces the First-in-Human Treatment with its Ground Breaking EyeCET ElectroTransfection Technology for Eye Diseases

 11 April 2017

Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development

 21 March 2017

Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman

 15 Septembre 2016

Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million

 30 May 2016

Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors

9 October 2015

Eyevensys closes €7.5m ($8.5m) in Series A financing

15 January 2015

Appointment of Francesco Sinigaglia as Chairman of the Board

28 March 2015

Eyevensys S.A.S announced the appointment of Mr. Raffy Kazandjian as CEO

11 April 2013

Eyevensys announces an equity investment by Boehringer Ingelheim Venture Fund